Navigation Links
Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
Date:4/1/2008

SAN DIEGO, April 1, 2008 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) and its operating unit InnerCool Therapies announced today that InnerCool has entered into a European commercialization agreement with Euromed Medizinisch GmbH (Euromed), a leading distributor of cardiology medical products. Under the terms of the agreement, Euromed will have exclusive marketing, sales and distribution rights in Austria, Germany and Switzerland for InnerCool's portfolio of temperature modulation systems. This agreement covers InnerCool's CoolBlue(TM), a nurse-friendly and cost-effective surface cooling temperature modulation system, which was launched in the U.S. market during the fourth quarter 2007, as well as InnerCool's, premium-priced, high-performance RapidBlue(TM) endovascular cooling system, which is expected to be launched in the U.S. market in the second quarter 2008. Using Euromed's marketing and sales force, sales of CoolBlue consoles and disposables are expected to begin in Europe this quarter, and sales of RapidBlue consoles and disposables are expected to begin next quarter.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

"We are pleased to have this distribution agreement with Euromed. They have a knowledgeable medical sales force with clinical support in our targeted markets, as well as extensive experience in selling temperature modulation products," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics and InnerCool Therapies. "This new European partnership, along with our recent distribution agreement for Australia and New Zealand, are consistent with our strategy of a
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
2. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
3. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
4. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
5. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
6. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
7. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
8. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
9. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
10. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
11. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 The custom stainless steel fabrication ... Show 2014. The Boston Area Chapter of ISPE (International ... day-long event for Wed., Oct. 1 at Gillette Stadium ... the largest in ISPE Boston’s long history, with more ... attendees expected. , HOLLOWAY AMERICA President David Simpson ...
(Date:9/30/2014)... Lyme Research Alliance (LRA), the ... at universities, today announced the awarding of seven grants ... and cure for Lyme and other tick-borne diseases. ... in its history—over 20 grant proposals—a 100 percent increase ... to receive so many solid applications from talented scientists ...
(Date:9/30/2014)... 30, 2014 SoundConnect, ... company is dedicated to supporting business communication solutions, ... Julie Power, a carrier services specialist ... solutions stays connected and productive at all times. ... movement of businesses to cloud communications services. ...
(Date:9/30/2014)... September 30, 2014 Rainbow Scientific, ... research products, recently opened an online store to ... culture product lines developed and manufactured by Biological ... store include Biological Industries’ Nutristem® serum-free, xeno-free reagents ... embryonic stem cell (hESC) culture. , The ...
Breaking Biology Technology:HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4SoundConnect Expands Carrier Services Division 2Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2
... Therapeutics,Inc. (Nasdaq: IMRX ), a biopharmaceutical company ... financial,results for the first quarter ended March 31, ... Highlights:, -- Entered into agreement with Abbott ... obligation under non-recourse promissory note issued in connection ...
... Spain, May 15 Forest,Laboratories, Inc. (NYSE: ... a webcast to discuss aclidinium bromide clinical and ... Annual Congress.,The webcast, which will include a slide ... May 21, 2008 at 9:30am New York time, ...
... Care Advisory Panel reacts to CMS final rule; ... identifies challenges, recommends ... Industries, Inc. and,the International Expert Wound Care Advisory ... to Improve Pressure,Ulcer Prevention and Treatment: Implications of ...
Cached Biology Technology:ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 2ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 3ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 4ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 5ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 6ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 7Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress 2International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 2International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 3
(Date:9/29/2014)... ago when the supercontinent of Pangea was starting to break ... different kinds of reptiles called phytosaurs and rauisuchids were at ... believed the two top predators didn,t interact much as the ... the land. But those ideas are changing, thanks largely to ... published online in September in the German journal ...
(Date:9/29/2014)... has significant anti-tumour activity in patients with advanced ... disease has progressed after chemotherapy, according to phase ... in Madrid, Spain. , "Reports of lung ... interest because these mutations may be associated with ... lead author Dr David Planchard, pulmonary oncologist at ...
(Date:9/29/2014)... 2014 NXT-ID, Inc. (Nasdaq: NXTD ... authentication company focused on the growing mobile commerce market, ... been named the Company,s Vice-President and Chief Financial Officer ... as Chief Financial Officer. Mr. Pereira will continue to ... a Director. Mr. Miceli, age 56, has ...
Breaking Biology News(10 mins):Tooth buried in bone shows prehistoric predators tangled across land, sea 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3NXT-ID, Inc. Names Vice-President and Chief Financial Officer 2NXT-ID, Inc. Names Vice-President and Chief Financial Officer 3
... Chalmers University of Technology have built a very simple ... directions, even though the antenna is smaller than the ... online journal Nature Communications this week ... very low concentrations of gases or biomolecules. A ...
... 2011 The Translational Genomics Research Institute (TGen) is ... $3.5 million grant from Susan G. Komen for the ... form of this cancer that disproportionately affects African-Americans. ... of physicians and scientists called Promise Grants, multi-million dollar, ...
... of Utah researchers have discovered a new class of compounds ... and inhibit it from infecting cells an early step ... virus. Development and laboratory testing of the potential new ... a study set for online publication by Friday in the ...
Cached Biology News:Bimetallic nanoantenna separates colors of light 2TGen breast cancer research benefits from $3.5 million Komen award 2TGen breast cancer research benefits from $3.5 million Komen award 3Targeting HIV's sugar coating 2Targeting HIV's sugar coating 3
Request Info...
Request Info...
... Nebulizers are available in two product models - ... two models is that the 6000AT+ includes a ... drier aerosol for improved detection limits and reduced ... a range of elements by 10-40 times. Note ...
...
Biology Products: